Abstract:The androgen receptor (AR) transcription factor plays a key role in the development and progression of prostate cancer, as is evident from the efficacy of androgen-deprivation therapy, AR is also the most frequently mutated gene, in castration resistant prostate cancer (CRPC). AR has therefore become an even more attractive therapeutic target in aggressive and disseminated prostate cancer. To investigate mechanisms of AR and AR target gene activation in different subpopulations of prostate cancer cells, a toolkit of AR expressor and androgen response element (ARE) reporter vectors were developed. Three ARE reporter vectors were constructed with different ARE consensus sequences in promoters linked to either fluorescence or luciferase reporter genes in lentiviral vector backbones. Cell lines transduced with the different vectors expressed the reporters in an androgen-dependent way according to fluorescence microscopy, flow cytometry and multi-well fluorescent and luminescence assays. Interestingly, the background reporter activity in androgen-depleted medium was significantly higher in LNCaP cells compared to the prostate transit amplifying epithelial cell lines, EP156T-AR and 957E/hTERT-AR with exogenous AR. The androgen-induced signal to background was much higher in the latter benign prostate cells than in LNCaP cells. Androgen-independent nuclear localization of AR was seen in LNCaP cells and reduced ARE-signaling was seen following treatment with abiraterone, an androgen synthesis inhibitor. The ARE reporter activity was significantly stronger when stimulated by androgens than by β-estradiol, progesterone and dexamethasone in all tested cell types. Finally, no androgen-induced ARE reporter activity was observed in tumorigenic mesenchymal progeny cells of EP156T cells following epithelial to mesenchymal transition. This underscores the observation that expression of the classical luminal differentiation transcriptome is restricted in mesenchymal type cells with or without AR expression, and presence of androgen.

Androgen Receptor Isoforms in Human Prostatic Cancer Tissue and LNCaP Cell Line.

[Expression of Androgen Receptor Isoforms in Normal Human Prostate].

The androgen receptor isoforms differentially expressed in normal human prostatic peripheral and transitional zones

Expressions of the Androgen Receptor in Normal Prostate, Benign Prostatic Hyperplasia and Prostate Cancer

Expression of Androgen Receptor in Breast Cancer and Its Prognostic Significance

Expression and transcription of androgen receptor in prostate cancer cell lines with different characteristics of androgen independence

Differential expression and function of AR isoforms in prostate cancer.

Changes of Androgen Receptor Expression in Hormonal Dependent Prostatic Cancer and Hormonal Independent Prostatic Cancer

Androgen Receptor Up-Regulates EphA3 Expression in Androgen-Dependent Prostate Cancer Cell Lines

Transactivity Alterations of Androgen Receptor Mutants in PC-3 Cells of Advanced Prostate Cancers

Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase

Androgen Receptor Mutants Detected in Recurrent Prostate Cancer Exhibit Diverse Functional Characteristics.

The Diverse and Contrasting Effects of Using Human Prostate Cancer Cell Lines to Study Androgen Receptor Roles in Prostate Cancer

Changes of Androgen Receptor and Insulin-Like Growth Factor-1 in LNCaP Prostate Cancer Cells Treated with Sex Hormones and Flutamide.

Expression of lncRNA PCGEM1 and AR co-localization in prostate cancer and tis signiifcance

The expressions and clinical significances of AR in prostate carcinoma

Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.

Linking Prostate Cancer Cell AR Heterogeneity to Distinct Castration and Enzalutamide Responses

Androgen Receptor Functioned As a Suppressor in the Prostate Cancer Cell Line PC3 in Vitro and in Vivo.

An Androgen Response Element Driven Reporter Assay for the Detection of Androgen Receptor Activity in Prostate Cells

[Both CK2 Catalytic Subunits Involves in Androgen Receptor Signaling in Prostate Cancer Cells].